I agree that autism is often innate and strongly heritable. But high heritability does not mean immutability, nor does it exclude environmental modulation, particularly when environmental factors may be widespread, shared, or interacting with biology in consistent ways.
I also agree with much of what you are arguing regarding the potential importance of germline and developmental programming effects.
But could you agree that even with a pre-existing heritable vulnerability, that environmental, metabolic, immune, or toxicant-related exposures could still influence developmental trajectory, severity, regression, or co-occurring medical burden in at least some individuals?
There is substantial evidence that core cellular processes — including mitochondrial function, redox balance, immune signaling, oxidative stress pathways, and metabolic signaling — directly influence neurodevelopment, including synaptic development, neuronal connectivity, pruning, plasticity, network regulation, and broader cytoarchitecture of the developing brain. These are not peripheral issues; they are fundamental developmental mechanisms.
One of the central questions in autism science is how extremely diverse risk factors — hundreds of genes, de novo mutations, maternal immune activation, prematurity, valproate exposure, mitochondrial dysfunction, inflammatory pathways, and other metabolic or environmental factors — converge onto overlapping developmental phenotypes.
Clinical experience with many autism families has also reinforced my interest in neurodevelopmental regression and developmental trajectory. Regression does not establish causation. But I do not think it is scientifically appropriate to simply assume that biological events temporally associated with major developmental changes are necessarily irrelevant or that the same outcome would have occurred regardless.
To me, this is about understanding how genetic vulnerability, developmental biology, metabolism, immune signaling, and environmental factors interact across development.
And on a final note, I do not appreciate the suggestion that my views ignore the last 20 years of autism research or that I am uninterested in scientific input from others. Quite the opposite — I actively seek out perspectives from researchers, clinicians, advocates, and families with a wide range of viewpoints and expertise.
I am also proud of the work accomplished at the first IACC meeting. The Committee advanced thoughtful, evidence-informed, common-sense recommendations focused on issues like safety, medical care, and support for those with profound autism — recommendations that passed with strong public and federal support.
That is part of why the intensity of the public attacks and coordinated efforts to discredit the new IACC have been disappointing and, frankly, make genuine collaboration more challenging. I still hope we can find ways to engage respectfully and constructively around both the science and the needs of individuals and families.